

IV and Oral Iron Drugs Market - Global Outlook and Forecast 2021-2026

<https://marketpublishers.com/r/IDA385BD974EN.html>

Date: February 2021

Pages: 342

Price: US\$ 3,750.00 (Single User License)

ID: IDA385BD974EN

Abstracts

In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global IV and Oral Iron Drugs Market Report

The global IV and oral iron drugs market by revenue is expected to grow at a CAGR of 11.6% during the period 2021–2026.

The global IV and oral iron drugs market is expected to grow due to the prevalence of iron deficiency (ID). This deficiency is a highly widespread nutritional disorder, affecting around one-fourth of the global population, especially women and children. It is one of the predominant causes of anemia. Anemia accounts for around 9% of the total global disease burden. Several chronic diseases are frequently associated with iron deficiency anemia (IDA) such as chronic kidney disease (CKD), chronic heart failure, cancer, and inflammatory bowel diseases. As anemia is associated with chronic fatigue, diminished well-being, and impaired cognitive function, the treatment with oral and IV iron drugs reduces the need for blood transfusion in patients. Further, the WHO rates ID as the most common and widespread nutritional disorder globally, and its prevalence is expected to grow with the aging population and the incidence of various chronic disorders.

The following factors are likely to contribute to the growth of the IV and Oral Iron Drugs market during the forecast period:

Strategic Collaborations & Licensing Opportunities

Investigational Iron Drugs

Increasing Availability of Branded Iron Therapeutics and Expanded Indication Approvals

The study considers the present scenario of the IV and Iron drugs market and its market dynamics for the period 2020-2026. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.

Global IV and Oral Iron Drugs Market Segmentation

The global IV and Oral iron drugs market research report includes a detailed segmentation by route of administration, application, patient group, distribution, geography. Expected launches of branded IV iron drugs in new markets and expanded indication approvals for existing commercially available brands are the key factors influencing the growth of IV iron drugs. The increased uptake of branded IV drugs in the US and European countries is also expected to contribute significantly during the forecast period. Moreover, the rise in global medicine and healthcare expenditure and high-sensitivity, accuracy, easy, and convenient access to intravenous iron dosages is likely to drive the demand for IV iron drugs over the next few years.

The growing prevalence of chronic kidney disease (CKD) and nephrological disorders across the world is increasing the application of iron drugs at a faster rate, and the trend is likely to continue during the forecast period. Across the globe, one in five men and one in four women have CKD among people above 65 years of age. Hence, a high prevalence of renal failures, particularly in developing countries such as China and India, where the number of older adults is increasing, is expected to affect market growth. Approximately 70% of patients with CKD suffer from iron deficiencies, which can aggravate renal anemia. Therefore, iron therapy with IV & oral iron drugs is an essential treatment option for CKD patients.

Adults constitute over 81% share of the global IV and oral iron drugs market. Adults dominate the market due to the high incidence and prevalence of ID and IDA in the elderly population across the globe. CKD is relatively common among adults, with a prevalence rate of up to 13%. With the increase in the incidence of diabetes and hypertension, CKD patients are likely to grow, thereby increasing the demand for iron drugs. Also, the percentage of the geriatric population is increasing at a significant rate worldwide, which is a key factor driving the growth of the segment.

Hospital pharmacies offer iron drugs with adequate discounts and rebates. Innovations in hospital pharmacy practice have led to the emergence of pharmacists working in community health services, aged care facilities, rehabilitation facilities, and general practice clinics. Such practices of hospital pharmacists are further driving the uptake of iron drugs via hospital pharmacies.

Route of Administration

Oral

Intravenous (IV)

Application

Nephrology

Obstetrics & Gynecology (OBGYN)

Surgery

Gastroenterology

Oncology

Heart Failure (HF)

Patient Group

Adult

Pediatric

Distribution

Hospital Pharmacies

Offline Retail Pharmacies

Online Channels

INSIGHTS BY VENDORS

Vifor Pharma and Daiichi Sankyo Company are the leading players in the global IV and oral iron drugs market. However, AMAG Pharmaceuticals, PHARMACOSMOS, Sanofi, Allergan, Akebia Therapeutics, and Shield Therapeutics are other prominent players in the market with notable shares. Vendors are competing on a wide variety of factors such as innovations, marketing strategies, and distribution channels. Global companies have a wide geographic footprint, diversified product portfolio, and a strong focus on product innovation, R&D, and business expansion activities. Key players are expected to drive sales and margin growth in their business by expanding sales organization, maintaining technology leadership through R&D, and continuing to build clinical evidence to support the benefits of the products as well as services.

Prominent Vendors

Vifor Pharma

Daiichi Sankyo Company

Other Prominent Vendors

AMAG Pharmaceuticals

Akebia Therapeutics

Shield Therapeutics

PHARMACOSMOS

Allergan

Sanofi

AOP Orphan Pharmaceuticals

Other Vendors

AZAD Pharma

Ciron Drugs & Pharmaceuticals

Pfizer

Rockwell Medical

Salveo Lifecare

Sunny Pharmaceutical

INSIGHTS BY GEOGRAPHY

The North American IV and oral iron drugs market share is expected to witness promising growth during the forecast period. The high uptake of branded iron drugs is one of the major reasons for strong growth. Vendors offering branded drugs are generating significantly higher revenue from the US than other markets. Also, the increased healthcare spending in the US and Canada is further contributing to the growth of the market. The prevalence of ID is likely to increase during the forecast period as the number of people with conditions such as CKD, CHF, IBD, and uterine bleeding is increasing in the country. Moreover, according to the United States Renal Data System (USRDS), the number of people suffering from CKD in the US alone was around 30 million people in 2020. A stressful lifestyle and the rise in chronic conditions are factors for the increase in the number of people with ID in the region.

Geography

North America

US

Canada

Europe

UK

Germany

France

Italy

Spain

APAC

China

India

Japan

South Korea

Australia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Saudi Arabia

Turkey

South Africa

KEY QUESTIONS ANSWERED

1. What is the IV and oral iron drugs market size and growth rate during the forecast period?
2. What is the impact of COVID-19 on the intravenous iron drugs market share?
3. Which regions are expected to observe high revenues for IV and oral drugs during the forecast period?
4. Who are the notable market players in the global IV and oral iron drugs market?
5. What are the opportunities and threats faced by key vendors in the market?

Contents

1 RESEARCH METHODOLOGY

2 RESEARCH OBJECTIVES

3 RESEARCH PROCESS

4 SCOPE & COVERAGE

4.1 Market Definition

4.1.1 Inclusions

4.1.2 Exclusions

4.2 Base Year

4.3 Scope of The Study

4.4 Market Segments

4.4.1 Market Segmentation by Route of Administration (ROA)

4.4.2 Market Segmentation by Application

4.4.3 Market Segmentation by Patient Group

4.4.4 Market Segmentation by Distribution

4.4.5 Market Segmentation by Geography

5 REPORT ASSUMPTIONS & CAVEATS

5.1 Key Caveats

5.2 Currency Conversion

5.3 Market Derivation

6 MARKET AT A GLANCE

7 INTRODUCTION

7.1 Iron Deficiency: An Overview

7.1.1 Background

7.1.2 Symptoms of ID

7.1.3 Different Causes of ID

7.1.4 Iron Drugs for the Treatment of ID

8 MARKET OPPORTUNITIES & TRENDS

- 8.1 Strategic Collaborations & Licensing Opportunities
- 8.2 Investigational Iron Drugs
- 8.3 Increasing Availability Of Branded Iron Therapeutics And Expanded Indication Approvals

9 MARKET GROWTH ENABLERS

- 9.1 Rising Incidence/Prevalence Of Iron Deficiency
- 9.2 High Demand For Dextran-Free Iv Iron Therapeutics
- 9.3 Growing Demand For Iron Replacement Therapies Among Kidney Disease Patients

10 MARKET RESTRAINTS

- 10.1 Presence of Alternative Options For Treating ID and IDA
 - 10.1.1 Natural Food Intake
 - 10.1.2 Combination Dietary Supplements & Nutritional Health Products
 - 10.1.3 Ayurvedic Medicine & TCM
- 10.2 Adverse Events Associated With Oral & IV Iron Drugs
- 10.3 Availability of Low-Cost Generic Iron Drugs

11 MARKET LANDSCAPE

- 11.1 Market Overview
 - 11.1.1 COVID-19 Impact on Global IV & Oral Iron Drugs Market
- 11.2 Market Size & Forecast
- 11.3 Five Forces Analysis
 - 11.3.1 Threat of New Entrants
 - 11.3.2 Bargaining Power of Suppliers
 - 11.3.3 Bargaining Power of Buyers
 - 11.3.4 Threat of Substitutes
 - 11.3.5 Competitive Rivalry

12 ROUTE OF ADMINISTRATION

- 12.1 Market Snapshot & Growth Engine
- 12.2 Market Overview
- 12.3 IV Iron Drugs
 - 12.3.1 Market Overview

- 12.3.2 Market Size & Forecast
- 12.3.3 IV Iron Drugs: Geography Segmentation
- 12.4 Oral Iron Drugs
 - 12.4.1 Market Overview
 - 12.4.2 Market Size & Forecast
 - 12.4.3 Oral Iron Drugs: Geography Segmentation

13 APPLICATION

- 13.1 Market Snapshot & Growth Engine
- 13.2 Market Overview
- 13.3 Nephrology
 - 13.3.1 Market Overview
 - 13.3.2 Market Size & Forecast
 - 13.3.3 Nephrology: Geography Segmentation
- 13.4 OBGYN
 - 13.4.1 Market Overview
 - 13.4.2 Market Size & Forecast
 - 13.4.3 OBGYN: Geography Segmentation
- 13.5 Surgery
 - 13.5.1 Market Overview
 - 13.5.2 Market Size & Forecast
 - 13.5.3 Surgery: Geography Segmentation
- 13.6 Gastroenterology
 - 13.6.1 Market Overview
 - 13.6.2 Market Size & Forecast
 - 13.6.3 Gastroenterology: Geography Segmentation
- 13.7 Oncology
 - 13.7.1 Market Overview
 - 13.7.2 Market Size & Forecast
 - 13.7.3 Oncology: Geography Segmentation
- 13.8 Heart Failure
 - 13.8.1 Market Overview
 - 13.8.2 Market Size & Forecast
 - 13.8.3 Heart Failure: Geography Segmentation

14 PATIENT GROUP

- 14.1 Market Snapshot & Growth Engine

14.2 Market Overview

14.3 Adult

14.3.1 Market Overview

14.3.2 Market Size & Forecast

14.3.3 Adult: Geography Segmentation

14.4 Pediatric

14.4.1 Market Overview

14.4.2 Market Size & Forecast

14.4.3 Pediatric: Geography Segmentation

15 DISTRIBUTION

15.1 Market Snapshot & Growth Engine

15.2 Market Overview

15.3 Hospital Pharmacies

15.3.1 Market Overview

15.3.2 Market Size & Forecast

15.3.3 Hospital Pharmacies: Geography Segmentation

15.4 Offline Retail Pharmacies

15.4.1 Market Overview

15.4.2 Market Size & Forecast

15.4.3 Offline Retail Pharmacies: Geography Segmentation

15.5 Online Channels

15.5.1 Market Overview

15.5.2 Market Size & Forecast

15.5.3 Online Channels: Geography Segmentation

16 GEOGRAPHY

16.1 Market Snapshot & Growth Engine

16.2 Geographic Overview

17 NORTH AMERICA

17.1 Market Overview

17.2 Market Size & Forecast

17.3 North America: Route of Administration Segmentation

17.4 North America: Application Segmentation

17.5 North America: Patient Group Segmentation

17.6 North America: Distribution Segmentation

17.7 Key Countries

17.7.1 US: Market Size & Forecast

17.7.2 Canada: Market Size & Forecast

18 EUROPE

18.1 Market Overview

18.2 Market Size & Forecast

18.3 Europe: Route Of Administration Segmentation

18.4 Europe: Application Segmentation

18.5 Europe: Patient Group Segmentation

18.6 Europe: Distribution Segmentation

18.7 Key Countries

18.7.1 Germany: Market Size & Forecast

18.7.2 UK: Market Size & Forecast

18.7.3 France: Market Size & Forecast

18.7.4 Italy: Market Size & Forecast

18.7.5 Spain: Market Size & Forecast

19 APAC

19.1 Market Overview

19.2 Market Size & Forecast

19.4 APAC: Route of Administration Segmentation

19.5 APAC: Application Segmentation

19.6 APAC: Patient Group Segmentation

19.7 APAC: Distribution Segmentation

19.8 Key Countries

19.8.1 Japan: Market Size & Forecast

19.8.2 China: Market Size & Forecast

19.8.3 Australia: Market Size & Forecast

19.8.4 South Korea: Market Size & Forecast

19.8.5 India: Market Size & Forecast

20 LATIN AMERICA

20.1 Market Overview

20.2 Market Size & Forecast

20.4 Latin America: Route of Administration Segmentation

20.5 Latin America: Application Segmentation

20.6 Latin America: Patient Group Segmentation

20.7 Latin America: Distribution Segmentation

20.8 Key Countries

20.8.1 Brazil: Market Size & Forecast

20.8.2 Mexico: Market Size & Forecast

20.8.3 Argentina: Market Size & Forecast

21 MIDDLE EAST & AFRICA

21.1 Market Overview

21.2 Market Size & Forecast

21.3 Middle East & Africa: Route Of Administration Segmentation

21.4 Middle East & Africa: Application Segmentation

21.5 Middle East & Africa: Patient Group Segmentation

21.6 Middle East & Africa: Distribution Segmentation

21.7 Key Countries

21.7.1 Turkey: Market Size & Forecast

21.7.2 South Africa: Market Size & Forecast

21.7.3 Saudi Arabia: Market Size & Forecast

22 COMPETITIVE LANDSCAPE

22.1 Competition Overview

22.2 Market Share Analysis

22.2.1 Vifor Pharma

22.2.2 Daiichi Sankyo Company

22.2.3 AMAG Pharmaceuticals

22.2.4 Akebia Therapeutics

23 KEY COMPANY PROFILES

23.1 Vifor Pharma

23.1.1 Business Overview

23.1.2 Product Offerings

23.1.3 Key Strategies

23.1.4 Key Strengths

23.1.5 Key Opportunities

23.2 Daiichi Sankyo Company

- 23.2.1 Business Overview
- 23.2.2 Product Offerings
- 23.2.3 Key Strategies
- 23.2.4 Key Strengths
- 23.2.5 Key Opportunities

24 OTHER PROMINENT VENDORS

24.1 AMAG Pharmaceuticals

- 24.1.1 Business Overview
- 24.1.2 Product Offerings
- 24.1.3 Key Strategies
- 24.1.4 Key Strengths
- 24.1.5 Key Opportunities

24.2 Akebia Therapeutics

- 24.2.1 Business Overview
- 24.2.2 Product Offerings
- 24.2.3 Key Strategies
- 24.2.4 Key Strengths
- 24.2.5 Key Opportunities

24.3 Shield Therapeutics

- 24.3.1 Business Overview
- 24.3.2 Product Offerings
- 24.3.3 Key Strategies
- 24.3.4 Key Strengths
- 24.3.5 Key Opportunities

24.4 PHARMACOSMOS

- 24.4.1 Business Overview
- 24.4.2 Product Offerings
- 24.4.3 Key Strategies
- 24.4.4 Key Strengths
- 24.4.5 Key Opportunities

24.5 Allergan

- 24.5.1 Business Overview
- 24.5.2 Product Offerings
- 24.5.3 Key Strategies
- 24.5.4 Key Strengths
- 24.5.5 Key Opportunities

24.6 Sanofi

24.6.1 Business Overview

24.6.2 Product Offerings

24.6.3 Key Strategies

24.6.4 Key Strengths

24.6.5 Key Opportunities

24.7 AOP Orphan Pharmaceuticals

24.7.1 Business Overview

24.7.2 Product Offerings

24.7.3 Key Strategies

24.7.4 Key Strengths

24.7.5 Key Opportunities

25 OTHER VENDORS

25.1 AZAD Pharma

25.1.1 Business Overview

25.1.2 Product Offerings

25.2 Ciron Drugs & Pharmaceuticals

25.2.1 Business Overview

25.2.2 Product Offerings

25.3 Pfizer

25.3.1 Business Overview

25.3.2 Product Offerings

25.4 Rockwell Medical

25.4.1 Business Overview

25.4.2 Product Offerings

25.5 Salveo Lifecare

25.5.1 Business Overview

25.5.2 Product Offerings

25.6 Sunny Pharmaceutical

25.6.1 Business Overview

25.6.2 Product Offerings

26 REPORT SUMMARY

26.1 Key Takeaways

26.2 Strategic Recommendations

27 QUANTITATIVE SUMMARY

27.1 Route of Administration

27.1.1 IV: Geography Segmentation

27.1.2 Oral: Geography Segmentation

27.2 Application

27.2.1 Nephrology: Geography Segmentation

27.2.2 Obgyn: Geography Segmentation

27.2.3 Surgery: Geography Segmentation

27.2.4 Gastroenterology: Geography Segmentation

27.2.5 Oncology: Geography Segmentation

27.2.6 Heart Failure: Geography Segmentation

27.3 Patient Group

27.3.1 Adult: Geography Segmentation

27.3.2 Pediatric: Geography Segmentation

27.4 Distribution

27.4.1 Hospital Pharmacies: Geography Segmentation

27.4.2 Offline Retail Pharmacies: Geography Segmentation

27.4.3 Online Channels: Geography Segmentation

27.5 Geography

27.5.1 North America: Route of Administration Segmentation

27.5.2 Europe: Route of Administration Segmentation

27.5.3 APAC: Route of Administration Segmentation

27.5.4 Latin America: Route of Administration Segmentation

27.5.5 Middle East & Africa: Route of Administration Segmentation

27.5.6 North America: Application Segmentation

27.5.7 Europe: Application Segmentation

27.5.8 APAC: Application Segmentation

27.5.9 Latin America: Application Segmentation

27.5.10 Middle East & Africa: Application Segmentation

27.5.11 North America: Patient Group Segmentation

27.5.12 Europe: Patient Group Segmentation

27.5.13 APAC: Patient Group Segmentation

27.5.14 Latin America: Patient Group Segmentation

27.5.15 Middle East & Africa: Patient Group Segmentation

27.5.16 North America: Distribution Segmentation

27.5.17 Europe: Distribution Segmentation

27.5.18 APAC: Distribution Segmentation

27.5.19 Latin America: Distribution Segmentation

27.5.20 Middle East & Africa: Distribution Segmentation

28 APPENDIX

28.1 Abbreviations

List Of Exhibits

LIST OF EXHIBITS

- Exhibit 1 Segmentation of Global IV & Oral Iron Drugs Market
- Exhibit 2 Market Size Calculation Approach 2020
- Exhibit 3 Major Negative Impacts of ID
- Exhibit 4 Some of the Most Common Symptoms of ID
- Exhibit 5 Global IV & Oral Iron Drugs Market by Geography 2020 (%)
- Exhibit 6 Global IV & Oral Iron Drugs Market by Route of Administration 2020 (%)
- Exhibit 7 Impact of Strategic Collaborations & Licensing Opportunities
- Exhibit 8 Impact of Investigational Iron Drugs
- Exhibit 9 Impact of Increasing Availability of Branded Iron Therapeutics and Expanded Indication Approvals
- Exhibit 10 Impact of Rising Incidence/Prevalence of Iron Deficiency
- Exhibit 11 Worldwide Prevalence of Anemia Among Children under Five Years 2010-2016 (%)
- Exhibit 12 Global Prevalence of Anemia in Different Population Groups
- Exhibit 13 Impact of High Demand for Dextran-free IV Iron Therapeutics
- Exhibit 14 Vifor Pharma (Ferinject Revenue 2017-2019) (\$ million)
- Exhibit 15 Daiichi Sankyo Company (Injectafer Revenue 2017-2019) (\$ million)
- Exhibit 16 AMAG Pharmaceuticals' (Feraheme Revenue 2017-2019) (\$ million)
- Exhibit 17 Impact of Growing Demand Iron Replacement Therapies Among Kidney Disease Patients
- Exhibit 18 The Underlying Causes of CKD and the Subsequent Contribution of Absolute or Functional Iron Deficiency to Renal Anemia
- Exhibit 19 Anemia Prevalence Rate Comparison Between General Population and CKD Patients
- Exhibit 20 Prevalence of Anemia in Patients with NDD-CKD (%)
- Exhibit 21 Impact of Presence of Alternative Options for Treating ID and IDA
- Exhibit 22 Popular Alternative Options for Treating ID/IDA
- Exhibit 23 Impact of Adverse Events Associated with Oral & IV Iron Drugs
- Exhibit 24 Impact of Availability of Low-cost Generic Iron Drugs
- Exhibit 25 Percentage Share of Prescription Iron Drugs by Region 2018
- Exhibit 26 Global IV & Oral Iron Drugs Market 2020-2026 (\$ million)
- Exhibit 27 Global IV & Oral Iron Drugs Market by Geography
- Exhibit 28 Global IV & Oral Iron Drugs Market by Route of Administration
- Exhibit 29 Global IV & Oral Iron Drugs Market by Application
- Exhibit 30 Global IV & Oral Iron Drugs Market by Patient Group

- Exhibit 31 Global IV & Oral Iron Drugs Market by Distribution
- Exhibit 32 Five Forces Analysis 2020
- Exhibit 33 Incremental Growth by Route of Administration 2020 & 2026
- Exhibit 34 Global IV & Oral Iron Drugs Market by Route of Administration
- Exhibit 35 Global IV & Oral Iron Drugs Market by Route of Administration: Incremental Growth
- Exhibit 36 Global IV & Oral Iron Drugs Market by Route of Administration: Absolute Growth
- Exhibit 37 Global IV & Oral Iron Drugs Market by IV Route of Administration: Incremental & Absolute Growth
- Exhibit 38 Global IV & Oral Iron Drugs Market by IV Iron Drugs 2020–2026 (\$ million)
- Exhibit 39 Incremental Growth by Geography 2020 & 2026
- Exhibit 40 Global IV & Oral Iron Drugs Market by Oral Route of Administration: Incremental & Absolute Growth
- Exhibit 41 Global IV & Oral Iron Drugs Market by Oral Drugs 2020–2026 (\$ million)
- Exhibit 42 Incremental Growth by Geography 2020 & 2026
- Exhibit 43 Incremental Growth by Application 2020 & 2026
- Exhibit 44 Global IV & Oral Iron Drugs Market by Application
- Exhibit 45 Global IV & Oral Iron Drugs Market by Application: Incremental Growth
- Exhibit 46 Global IV & Oral Iron Drugs Market by Application: Absolute Growth
- Exhibit 47 Global IV & Oral Iron Drugs Market by Nephrology: Incremental & Absolute Growth
- Exhibit 48 Global IV & Oral Iron Drugs Market by Nephrology 2020–2026 (\$ million)
- Exhibit 49 Incremental Growth by Geography 2020 & 2026
- Exhibit 50 Global IV & Oral Iron Drugs Market by OBGYN: Incremental & Absolute Growth
- Exhibit 51 Global IV & Oral Iron Drugs Market by OBGYN 2020–2026 (\$ million)
- Exhibit 52 Incremental Growth by Geography 2020 & 2026
- Exhibit 53 Global IV & Oral Iron Drugs Market by Surgery: Incremental & Absolute Growth
- Exhibit 54 Global IV & Oral Iron Drugs Market by Surgery 2020–2026 (\$ million)
- Exhibit 55 Incremental Growth by Geography 2020 & 2026
- Exhibit 56 Global IV & Oral Iron Drugs Market by Gastroenterology: Incremental & Absolute Growth
- Exhibit 57 Prevalence of Diagnosed GI Conditions in Selected Geographies 2018
- Exhibit 58 Global IV & Oral Iron Drugs Market by Gastroenterology 2020–2026 (\$ million)
- Exhibit 59 Incremental Growth by Geography 2020 & 2026
- Exhibit 60 Global Cancer Incidence 2018 (%)

- Exhibit 61 Global IV & Oral Iron Drugs Market by Oncology: Incremental & Absolute Growth
- Exhibit 62 Key Benefits of Iron Therapy in Cancer Patients
- Exhibit 63 Global IV & Oral Iron Drugs Market by Oncology 2020–2026 (\$ million)
- Exhibit 64 Incremental Growth by Geography 2020 & 2026
- Exhibit 65 Global IV & Oral Iron Drugs Market by Heart Failure: Incremental & Absolute Growth
- Exhibit 66 Global IV & Oral Iron Drugs Market by Heart Failure 2020–2026 (\$ million)
- Exhibit 67 Incremental Growth by Geography 2020 & 2026
- Exhibit 68 Incremental Growth by Patient Group 2020 & 2026
- Exhibit 69 Global IV & Oral Iron Drugs Market by Patient Group
- Exhibit 70 Global IV & Oral Iron Drugs Market by Patient Group: Incremental Growth
- Exhibit 71 Global IV & Oral Iron Drugs Market by Patient Group: Absolute Growth
- Exhibit 72 Global IV & Oral Iron Drugs Market by Adult: Incremental & Absolute Growth
- Exhibit 73 Global IV & Oral Iron Drugs Market by Adults 2020–2026 (\$ million)
- Exhibit 74 Incremental Growth by Geography 2020 & 2026
- Exhibit 75 Global Pediatric IV & Oral Iron Drugs Market: Incremental & Absolute Growth
- Exhibit 76 Global Pediatric IV & Oral Iron Drugs Market 2020–2026 (\$ million)
- Exhibit 77 Incremental Growth by Geography 2020 & 2026
- Exhibit 78 Incremental Growth by Distribution 2020 & 2026
- Exhibit 79 Global IV & Oral Iron Drugs Market by Distribution
- Exhibit 80 Global IV & Oral Iron Drugs Market by Distribution: Incremental Growth
- Exhibit 81 Global IV & Oral Iron Drugs Market by Distribution: Absolute Growth
- Exhibit 82 Global IV & Oral Iron Drugs Market by Hospital Pharmacies: Incremental & Absolute Growth
- Exhibit 83 Key Role of Hospital Pharmacies in Patient Education
- Exhibit 84 Global IV & Oral Iron Drugs Market by Hospital Pharmacies 2020–2026 (\$ million)
- Exhibit 85 Incremental Growth by Geography 2020 & 2026
- Exhibit 86 Global IV & Oral Iron Drugs Market by Offline Retail Pharmacies: Incremental & Absolute Growth
- Exhibit 87 Global IV & Oral Iron Drugs Market by Offline Retail Pharmacies 2020–2026 (\$ million)
- Exhibit 88 Incremental Growth by Geography 2020 & 2026
- Exhibit 89 Global IV & Oral Iron Drugs Market by Online Channels: Incremental & Absolute Growth
- Exhibit 90 Global IV & Oral Iron Drugs Market by Online Channels 2020–2026 (\$ million)
- Exhibit 91 Incremental Growth by Geography 2020 & 2026

- Exhibit 92 Incremental Growth by Geography 2020 & 2026
- Exhibit 93 Global IV & Oral Iron Drugs Market by Geography
- Exhibit 94 Global IV & Oral Iron Drugs Market by Geography 2020: Key Countries (\$ million)
- Exhibit 95 Global IV & Oral Iron Drugs Market by Geography: Incremental Growth
- Exhibit 96 Global IV & Oral Iron Drugs Market by Geography: Absolute Growth
- Exhibit 97 North America IV & Oral Iron Drugs Market 2020: Key Countries
- Exhibit 98 North America IV & Oral Iron Drugs Market: Absolute & Incremental Growth
- Exhibit 99 IV & Oral Iron Drugs Market in North America 2020–2026 (\$ million)
- Exhibit 100 Incremental Growth by Route of Administration 2020 & 2026
- Exhibit 101 Incremental Growth by Application 2020 & 2026
- Exhibit 102 Incremental Growth by Patient Group 2020 & 2026
- Exhibit 103 Incremental Growth by Distribution 2020 & 2026
- Exhibit 104 Incremental Growth in North America 2020 & 2026
- Exhibit 105 Prevalence of CKD in US 2001–2016 (%)
- Exhibit 106 IV & Oral Iron Drugs Market in US 2020–2026 (\$ million)
- Exhibit 107 IV & Oral Iron Drugs Market in Canada 2020–2026 (\$ million)
- Exhibit 108 Europe IV & Oral Iron Drugs Market 2020: Key Countries
- Exhibit 109 IV & Oral Iron Drugs Market in Europe: Incremental & Absolute Growth
- Exhibit 110 IV & Oral Iron Drugs Market in Europe 2020–2026 (\$ million)
- Exhibit 111 Incremental Growth by Route of Administration 2020 & 2026
- Exhibit 112 Incremental Growth by Application 2020 & 2026
- Exhibit 113 Incremental Growth by Patient Group 2020 & 2026
- Exhibit 114 Incremental Growth by Distribution 2020 & 2026
- Exhibit 115 Incremental Growth in Europe 2020 & 2026
- Exhibit 116 IV & Oral Iron Drugs Market in Germany 2020–2026 (\$ million)
- Exhibit 117 IV & Oral Iron Drugs Market in UK 2020–2026 (\$ million)
- Exhibit 118 IV & Oral Iron Drugs Market in France 2020–2026 (\$ million)
- Exhibit 119 IV & Oral Iron Drugs Market in Italy 2020–2026 (\$ million)
- Exhibit 120 IV & Oral Iron Drugs Market in Spain 2020–2026 (\$ million)
- Exhibit 121 APAC IV & Oral Iron Drugs Market 2020: Key Countries
- Exhibit 122 APAC IV & Oral Iron Drugs Market: Incremental & Absolute Growth
- Exhibit 123 IV & Oral Iron Drugs Market in APAC 2020–2026 (\$ million)
- Exhibit 124 Health Access & Quality Index Score for Key APAC Countries 2016
- Exhibit 125 Incremental Growth by Route of Administration 2020 & 2026
- Exhibit 126 Incremental Growth by Application 2020 & 2026
- Exhibit 127 Incremental Growth by Patient Group 2020 & 2026
- Exhibit 128 Incremental Growth by Distribution 2020 & 2026
- Exhibit 129 Incremental Growth in APAC 2020 & 2026

- Exhibit 130 IV & Oral Iron Drugs Market in Japan 2020–2026 (\$ million)
- Exhibit 131 IV & Oral Iron Drugs Market in China 2020–2026 (\$ million)
- Exhibit 132 IV & Oral Iron Drugs Market in Australia 2020–2026 (\$ million)
- Exhibit 133 IV & Oral Iron Drugs Market in South Korea 2020–2026 (\$ million)
- Exhibit 134 Prevalence of Anemia in Children & Adults 2005?2006 & 2015?2016 in India
- Exhibit 135 IV & Oral Iron Drugs Market in India 2020–2026 (\$ million)
- Exhibit 136 Latin America IV & Oral Iron Drugs Market 2020: Key Countries
- Exhibit 137 IV & Oral Iron Drugs Market in Latin America: Incremental & Absolute Growth
- Exhibit 138 IV & Oral Iron Drugs Market in Latin America 2020–2026 (\$ million)
- Exhibit 139 Incremental Growth by Route of Administration 2020 & 2026
- Exhibit 140 Incremental Growth by Application 2020 & 2026
- Exhibit 141 Incremental Growth by Patient Group 2020 & 2026
- Exhibit 142 Incremental Growth by Distribution 2020 & 2026
- Exhibit 143 Incremental Growth in Latin America 2020 & 2026
- Exhibit 144 IV & Oral Iron Drugs Market in Brazil 2020–2026 (\$ million)
- Exhibit 145 IV & Oral Iron Drugs Market in Mexico 2020–2026 (\$ million)
- Exhibit 146 IV & Oral Iron Drugs Market in Argentina 2020–2026 (\$ million)
- Exhibit 147 Middle East & Africa IV & Oral Iron Drugs Market 2020: Key Countries
- Exhibit 148 Middle East & Africa IV & Oral Iron Drugs Market: Incremental & Absolute Growth
- Exhibit 149 IV & Oral Iron Drugs Market in Middle East & Africa 2020–2026 (\$ million)
- Exhibit 150 Incremental Growth by Route of Administration 2020 & 2026
- Exhibit 151 Incremental Growth by Application 2020 & 2026
- Exhibit 152 Incremental Growth by Patient Group 2020 & 2026
- Exhibit 153 Incremental Growth by Distribution 2020 & 2026
- Exhibit 154 Incremental Growth in Middle East & Africa 2020 & 2026
- Exhibit 155 IV & Oral Iron Drugs Market in Turkey 2020–2026 (\$ million)
- Exhibit 156 IV & Oral Iron Drugs Market in South Africa 2020–2026 (\$ million)
- Exhibit 157 IV & Oral Iron Drugs Market in Saudi Arabia 2020–2026 (\$ million)
- Exhibit 158 Vifor Pharma: R&D Expenditure 2017?2019 (\$ million)
- Exhibit 159 Vifor Pharma: Revenue by Geography 2019 (%)
- Exhibit 160 Daiichi Sankyo Company: Revenue by Key Products 2018 & 2019 (\$ billion)
- Exhibit 161 AMAG Pharmaceuticals: R&D Expenditure 2017?2019 (\$ million)
- Exhibit 162 AMAG Pharmaceuticals: Feraheme Revenue 2017?2019 (\$ million)
- Exhibit 163 Akebia Therapeutics: R&D Expenditure 2017?2019 (\$ million)

List Of Tables

LIST OF TABLES

Table 1 Key Caveats

Table 2 Currency Conversion 2013-2020

Table 3 Standard Requirement of Iron in Different Patient Groups

Table 4 Oral & IV Iron Therapy: Advantages and Disadvantages

Table 5 Key Characteristics of Oral and IV Iron Drugs

Table 6 Major Strategic Collaborations and Licensing Partnerships

Table 7 Key Investigational Iron Drugs

Table 8 Recent Approval/Launch of Popular Iron Drugs in Various Countries/Regions

Table 9 Recent Expanded Indication Approval of Popular Iron Drugs in Various Countries/Regions

Table 10 Percentage of Patients Affected with IDA in Various Diseases

Table 11 Popular Prescription Drugs Used for Treating IDA in CKD Patients

Table 12 Most Popular Food Sources with High Iron Levels

Table 13 Popular IV Iron Drugs by Prominent Players

Table 14 Most Common Oral Iron Drug Preparations

Table 15 Popular Oral Iron Drugs by Prominent Players

Table 16 Popular IV Iron Drugs Available for Treating ID in CKD Patients

Table 17 Factors Leading to the Development of ID and IDA Among Pregnant Women

Table 18 Iron Supplementation Dosage Among Children

Table 19 Iron Therapy Recommendation for Different Stages of Iron Deficiency in Surgical Patients

Table 20 Iron Therapy Recommendation for Different Stages of Iron Deficiency in Surgical Patients

Table 21 Iron-Containing Proteins Altered in Heart Failure Patients

Table 22 Current Guideline Recommendations for IV Iron in Heart Failure Patients

Table 23 Key Causes of Iron Deficiency Anemia in Adults

Table 24 Common Oral Iron Preparations

Table 25 Iron Recommendations for Pediatric Age Groups

Table 26 Prevalence of ID and IDA in Major European Countries

Table 27 Key Competitive Factors in the Global IV & Oral Iron Drugs Market

Table 28 Global IV & Oral Iron Drugs Market: Vendors Ranking 2020

Table 29 Vifor Pharma: Major Product Offerings

Table 30 Daiichi Sankyo Company: Major Product Offerings

Table 31 AMAG Pharmaceuticals: Major Product Offerings

Table 32 Akebia Therapeutics: Major Product Offerings

- Table 33 Shield Therapeutics: Major Product Offerings
- Table 34 PHARMACOSMOS: Major Product Offerings
- Table 35 Allergan: Major Product Offerings
- Table 36 Sanofi: Major Product Offerings
- Table 37 AOP Orphan Pharmaceuticals: Major Product Offerings
- Table 38 AZAD Pharma: Major Product Offerings
- Table 39 Ciron Drugs & Pharmaceuticals: Major Product Offerings
- Table 40 Pfizer: Major Product Offerings
- Table 41 Rockwell Medical: Major Product Offerings
- Table 42 Salveo Lifecare: Major Product Offerings
- Table 43 Sunny Pharmaceutical: Major Product Offerings
- Table 44 Global IV & Oral Iron Drugs Market by Route of Administration 2020?2026 (\$ million)
- Table 45 Global IV & Oral Iron Drugs Market by Route of Administration 2020?2026 (%)
- Table 46 IV Segment of IV & Oral Iron Drugs Market by Geography 2020?2026 (\$ million)
- Table 47 IV Segment of IV & Oral Iron Drugs Market by Geography 2020?2026 (%)
- Table 48 Oral Segment of IV & Oral Iron Drugs Market by Geography 2020?2026 (\$ million)
- Table 49 Oral Segment of IV & Oral Iron Drugs Market by Geography 2020?2026 (%)
- Table 50 Global IV & Oral Iron Drugs Market by Application 2020?2026 (\$ million)
- Table 51 Global IV & Oral Iron Drugs Market by Application 2020?2026 (%)
- Table 52 Nephrology IV & Oral Iron Drugs Market by Geography 2020?2026 (\$ million)
- Table 53 Nephrology IV & Oral Iron Drugs Market by Geography 2020?2026 (%)
- Table 54 OBGYN IV & Oral Iron Drugs Market by Geography 2020?2026 (\$ million)
- Table 55 OBGYN IV & Oral Iron Drugs Market by Geography 2020?2026 (%)
- Table 56 Surgery IV & Oral Iron Drugs Market by Geography 2020?2026 (\$ million)
- Table 57 Surgery IV & Oral Iron Drugs Market by Geography 2020?2026 (%)
- Table 58 Gastroenterology IV & Oral Iron Drugs Market by Geography 2020?2026 (\$ million)
- Table 59 Gastroenterology IV & Oral Iron Drugs Market by Geography 2020?2026 (%)
- Table 60 Oncology IV & Oral Iron Drugs Market by Geography 2020?2026 (\$ million)
- Table 61 Oncology IV & Oral Iron Drugs Market by Geography 2020?2026 (%)
- Table 62 Heart Failure IV & Oral Iron Drugs Market by Geography 2020?2026 (\$ million)
- Table 63 Heart Failure IV & Oral Iron Drugs Market by Geography 2020?2026 (%)
- Table 64 Global IV & Oral Iron Drugs Market by Patient Group 2020?2026 (\$ million)
- Table 65 Global IV & Oral Iron Drugs Market by Patient Group 2020?2026 (%)
- Table 66 Adult IV & Oral Iron Drugs Market by Geography 2020?2026 (\$ million)

- Table 67 Adult IV & Oral Iron Drugs Market by Geography 2020?2026 (%)
- Table 68 Pediatric IV & Oral Iron Drugs Market by Geography 2020?2026 (\$ million)
- Table 69 Pediatric IV & Oral Iron Drugs Market by Geography 2020?2026 (%)
- Table 70 Global IV & Oral Iron Drugs Market by Distribution 2020?2026 (\$ million)
- Table 71 Global IV & Oral Iron Drugs Market by Distribution 2020?2026 (%)
- Table 72 Hospital Pharmacies IV & Oral Iron Drugs Market by Geography 2020?2026 (\$ million)
- Table 73 Hospital Pharmacies IV & Oral Iron Drugs Market by Geography 2020?2026 (%)
- Table 74 Offline Retail Pharmacies IV & Oral Iron Drugs Market by Geography 2020?2026 (\$ million)
- Table 75 Offline Retail Pharmacies IV & Oral Iron Drugs Market by Geography 2020?2026 (%)
- Table 76 Online Channels IV & Oral Iron Drugs Market by Geography 2020?2026 (\$ million)
- Table 77 Online Channels IV & Oral Iron Drugs Market by Geography 2020?2026 (%)
- Table 78 Global IV & Oral Iron Drugs Market by Geography 2020?2026 (\$ million)
- Table 79 Global IV & Oral Iron Drugs Market by Geography 2020?2026 (%)
- Table 80 North America IV & Oral Iron Drugs Market by Route of Administration 2020?2026 (\$ million)
- Table 81 North America IV & Oral Iron Drugs Market by Route of Administration 2020?2026 (%)
- Table 82 Europe IV & Oral Iron Drugs Market by Route of Administration 2020?2026 (\$ million)
- Table 83 Europe IV & Oral Iron Drugs Market by Route of Administration 2020?2026 (%)
- Table 84 APAC IV & Oral Iron Drugs Market by Route of Administration 2020?2026 (\$ million)
- Table 85 APAC IV & Oral Iron Drugs Market by Route of Administration 2020?2026 (%)
- Table 86 Latin America IV & Oral Iron Drugs Market by Route of Administration 2020?2026 (\$ million)
- Table 87 Latin America IV & Oral Iron Drugs Market by Route of Administration 2020?2026 (%)
- Table 88 Middle East & Africa IV & Oral Iron Drugs Market by Route of Administration 2020?2026 (\$ million)
- Table 89 Middle East & Africa IV & Oral Iron Drugs Market by Route of Administration 2020?2026 (%)
- Table 90 North America IV & Oral Iron Drugs Market by Application 2020?2026 (\$ million)

Table 91 North America IV & Oral Iron Drugs Market by Application 2020?2026 (%)

Table 92 Europe IV & Oral Iron Drugs Market by Application 2020?2026 (\$ million)

Table 93 Europe IV & Oral Iron Drugs Market by Application 2020?2026 (%)

Table 94 APAC IV & Oral Iron Drugs Market by Application 2020?2026 (\$ million)

Table 95 APAC IV & Oral Iron Drugs Market by Application 2020?2026 (%)

Table 96 Latin America IV & Oral Iron Drugs Market by Application 2020?2026 (\$ million)

Table 97 Latin America IV & Oral Iron Drugs Market by Application 2020?2026 (%)

Table 98 Middle East & Africa IV & Oral Iron Drugs Market by Application 2020?2026 (\$ million)

Table 99 Middle East & Africa IV & Oral Iron Drugs Market by Application 2020?2026 (%)

Table 100 North America IV & Oral Iron Drugs Market by Patient Group 2020?2026 (\$ million)

Table 101 North America IV & Oral Iron Drugs Market by Patient Group 2020?2026 (%)

Table 102 Europe IV & Oral Iron Drugs Market by Patient Group 2020?2026 (\$ million)

Table 103 Europe IV & Oral Iron Drugs Market by Patient Group 2020?2026 (%)

Table 104 APAC IV & Oral Iron Drugs Market by Patient Group 2020?2026 (\$ million)

Table 105 APAC IV & Oral Iron Drugs Market by Patient Group 2020?2026 (%)

Table 106 Latin America IV & Oral Iron Drugs Market by Patient Group 2020?2026 (\$ million)

Table 107 Latin America IV & Oral Iron Drugs Market by Patient Group 2020?2026 (%)

Table 108 Middle East & Africa IV & Oral Iron Drugs Market by Patient Group 2020?2026 (\$ million)

Table 109 Middle East & Africa IV & Oral Iron Drugs Market by Patient Group 2020?2026 (%)

Table 110 North America IV & Oral Iron Drugs Market by Distribution 2020?2026 (\$ million)

Table 111 North America IV & Oral Iron Drugs Market by Distribution 2020?2026 (%)

Table 112 Europe IV & Oral Iron Drugs Market by Distribution 2020?2026 (\$ million)

Table 113 Europe IV & Oral Iron Drugs Market by Distribution 2020?2026 (%)

Table 114 APAC IV & Oral Iron Drugs Market by Distribution 2020?2026 (\$ million)

Table 115 APAC IV & Oral Iron Drugs Market by Distribution 2020?2026 (%)

Table 116 Latin America IV & Oral Iron Drugs Market by Distribution 2020?2026 (\$ million)

Table 117 Latin America IV & Oral Iron Drugs Market by Distribution 2020?2026 (%)

Table 118 Middle East & Africa IV & Oral Iron Drugs Market by Distribution 2020?2026 (\$ million)

Table 119 Middle East & Africa IV & Oral Iron Drugs Market by Distribution 2020?2026

(%)

I would like to order

Product name: IV and Oral Iron Drugs Market - Global Outlook and Forecast 2021-2026

Product link: <https://marketpublishers.com/r/IDA385BD974EN.html>

Price: US\$ 3,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IDA385BD974EN.html>